HCW Biologics Receives US Patent Allowance for HCW9302 in Alopecia Areata

09:29 AM EDT, 09/02/2026 (MT Newswires) -- HCW Biologics (HCWB) has received a Notice of Allowance from the US Patent and Trademark Office for claims covering the use of HCW9302 to treat alopecia areata, the company said Wednesday. The allowance adds to four recently issued US patents covering HCW9302 compositions, nucleic acids and vectors, as well as methods of treating other autoimmune diseases, HCW Biologics said. HCW9302 is an IL-2-based immunotherapeutic for the treatment of autoimmune diseases through the expansion and activation of regulatory T cells, the company said. Shares of HCW Biologics were 3.5% higher in Wednesday premarket activity.